Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
What: Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference Call When: Monday, August 4 at 10:30 a.m. ET /7:30 a.m. PT Where: www.isispharm.com How: Live on the Internet.
The Motley Fool
ISIS Pharmaceuticals, Inc. is The Best Stock Today
The Motley Fool's Better Stock Today tournament has declared a winner! Among the 32 companies pitted against each other our reader's voices your voice were heard loud and clear : Isis Pharmaceuticals is the best stock today.
Applied Clinical Trials
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
Isis Pharmaceuticals Inc 1,800 Shares of Regulus Therapeutics Stock
Regulus Therapeutics Director Isis Pharmaceuticals Inc 1,800 shares of the company's stock in a transaction that occurred on Wednesday, July 9th.
Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For...
"Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.
Contract Pharma Breaking News
Isis Earns GSK Milestone
Isis Pharmaceuticals, Inc. has earned a $1 million payment from GlaxoSmithKline for the advancement of its development program for antisense drugs to treat hepatitis B virus .